Compare Expensify Inc (EXFY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Expensify (EXFY) trades at $2.22, down 10.12% in the past 24 hours, with a bullish technical signal from moving averages and a neutral RSI. Recent Q2 2026 earnings showed a beat on EPS and a return to non-GAAP profitability, with revenue of $33.9 million. The company is expanding its AI-native solutions and European card offerings, supported by positive cash flow trends.

Outlook is cautiously optimistic due to earnings improvements and strategic expansions, but risks include persistent net losses, high P/E ratio of 258.82, and competitive pressures in expense management software. Analyst consensus is mixed with 44% buy ratings.

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.